Abstract

The COVID-19 pandemic, an unprecedented global health and economic crisis, profoundly disrupted businesses across the world, including India’s crucial pharmaceutical sector. While large pharmaceutical multinationals have dominated pandemic-era research and policy attention, there has been comparatively little empirical work on Small and Medium Enterprises (SMEs), which constitute the backbone of India’s pharmaceutical manufacturing capacity. This study seeks to fill this gap by analysing the impact of COVID-19 on the financial performance of three representative Indian pharmaceutical SMEs—Jagsonpal Pharmaceuticals Ltd, FDC Ltd, and Lincoln Pharmaceuticals Ltd—through rigorous pre-pandemic (2017–2019) and post-pandemic (2020–2022) financial analysis. Adopting a descriptive and comparative research design, the paper leverages secondary data sourced from company annual reports, stock exchange filings, and verified financial databases. Key financial performance indicators—profitability (Net Profit Margin, Return on Equity, Return on Assets), liquidity (Current Ratio, Quick Ratio), and solvency (Debt-to-Equity Ratio)—were calculated and compared over the study periods. Statistical validation was performed using paired t-tests to assess the significance of pre- and post-pandemic changes. The conceptual framework draws upon theories of SME resilience, particularly the Resource-Based View and Dynamic Capabilities Theory, to interpret results beyond simple ratio movement. Findings reveal that, although all three SMEs exhibited improved profitability, stronger liquidity, and reduced leverage following the pandemic, these changes were not statistically significant at the 5% confidence level. The patterns suggest that strategic cost management, operational restructuring, and diversification of supply chains—rather than the direct effects of the pandemic—were key drivers of financial improvement. Jagsonpal’s marked recovery is linked to internal financial controls and product realignment, while Lincoln’s stability derives from cash management and rapid debt reduction. The research underscores the need for targeted policy support, digital transformation incentives, and indigenous API development to secure India’s pharmaceutical supply chain and export competitiveness in a post-pandemic world.